Tilray logo
Tilray TLRY
$ 11.19 -7.9%

Quarterly report 2025-Q3
added 10-09-2025

report update icon

Tilray Income Statement 2011-2025 | TLRY

Annual Income Statement Tilray

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.19 B 1.71 B 1.89 B 1.73 B 9.47 B 6.43 T - - - - - - -

Shares

618 M 481 M 270 M 216 M 203 M 83 B - - - - - - -

Historical Prices

1.93 3.55 7.03 8.26 17.1 70.5 - - - - - - -

Net Income

-1.45 B -477 M -367 M -103 M -16.5 M 29.4 M 4.2 M 398 K -6.54 M -132 K -44.3 K -95.8 K -

Revenue

627 M 628 M 513 M 405 M 237 M 36.9 M 20.4 M 8.43 M 551 K - - - -

Cost of Revenue

480 M 512 M 390 M 309 M 190 M 28.9 M 9.16 M 9.97 M - - - - -

Gross Profit

147 M 117 M 123 M 96.1 M 75.4 M 40.9 M 17.3 M 5.98 M 795 K - - - -

Operating Income

-1.37 B -610 M -132 M -104 M -304 M -57.8 M -7.5 M -7.05 M - - - - -

Interest Expense

46.6 M 39.7 M 30.9 M 25.6 M 2.5 M 2.01 M 12 K -1 K - - - - -

EBITDA

-1.37 B -610 M -132 M -68.3 M -49.8 M -3.25 M 3.06 M -729 K -6.62 M -135 K -47.8 K -97.8 K -

Operating Expenses

1.52 B 727 M 255 M 200 M 139 M 48.1 M 15.2 M 7.07 M 7.47 M - - - -

General and Administrative Expenses

165 M 163 M 112 M 93.8 M 95.8 M 31.8 M 7.08 M 2.89 M 6.62 M 124 K 47.8 K 97.8 K -

All numbers in USD currency

Quarterly Income Statement Tilray

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

1.06 B 1.06 B 908 M 983 M 875 M 832 M 754 M 832 M 691 M 657 M 616 M 612 M 575 M 533 M 486 M 460 M 449 M 455 M 265 M 243 M 242 M 125 M 106 M - 98.1 M 97.2 M 94.9 M - 93.1 M 75 M 75 M - 75 M 75 M - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-322 K - -789 M -85.3 M -39.2 M - -92.7 M -49 M -71.5 M - -1.17 B -69.5 M -73.5 M -143 M 43.2 M -201 K -41.6 M -41.8 M -341 M -2.95 M -2.32 M -81.7 M -184 M -219 M -36.4 M -36.3 M -29.4 M -31 M -18.7 M -12.8 M -5.18 M -2.93 M -1.77 M -2.44 M -679 K - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

210 M - 186 M 211 M 200 M - 188 M 194 M 177 M - 146 M 144 M 153 M 297 M 152 M 155 M 168 M 323 M 124 M 129 M 117 M -1.33 M -1.75 M 46.9 M 51.1 M 45.9 M 23 M 15.5 M 10 M 9.74 M 7.81 M 5.11 M 5.41 M 4.99 M 5.03 M - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

152 M - 134 M 150 M 140 M - 139 M 146 M 133 M - 157 M 101 M 105 M 209 M 112 M 122 M 117 M 239 M 34.5 M 94.2 M 82.5 M - 41.2 M - 35.2 M 33.6 M 17.7 M - 6.98 M 5.57 M 3.91 M - 2.44 M 2.28 M - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

57.5 M - 52 M 61.2 M 59.7 M - 49.4 M 47.4 M 44.2 M - -11.7 M 42.9 M 48.6 M 88.7 M 39.8 M 32.8 M 51 M 83.7 M 13.5 M 16.6 M 3.33 M -5.82 M 10.9 M -57 M 15.9 M 12.3 M 5.38 M 3.13 M 3.07 M 4.18 M 3.9 M 2.93 M 2.97 M 2.71 M 2.77 M - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

2.09 M - -760 M -42.2 M -36.6 M - -82.1 M -41.8 M -34.4 M - -1.21 B -51.8 M -21.2 M -73 M -18.1 M -55.5 M -69.4 M -125 M -73.3 M -26 M -32.8 M -75.8 M -71.2 M -217 M -23.8 M -33 M -28.4 M -22.9 M -20 M -11 M -3.74 M -2.61 M -2.18 M -2.32 M -388 K - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - 12.6 M - - - -4.4 M - 1.21 M -18.4 M -33 M -51.4 M 71 M 65.6 M 191 K 115 M 1.52 M 1.8 M 38 K -333 K -4.65 M - 1.12 M 1.22 M 3.84 M - 225 K 76 K 121 K - 9 K -20 K - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - - - - - - - -51.8 M 12.9 M -73 M 6.51 M -26.5 M -30 M -48.1 M -68.4 M -21.8 M -21.8 M -72.5 M -66.7 M -217 M -13.3 M -27.2 M -25.7 M -22.9 M -17.5 M -9.84 M -3.26 M -2.61 M -780 K -1.36 M -388 K - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

55.4 M - 812 M 103 M 96.3 M - 131 M 89.2 M 78.6 M - 1.2 B 94.7 M 69.8 M 162 M 57.9 M 88.3 M 120 M 209 M 54.5 M 61.2 M 43.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

41.1 M - 39.2 M 46 M 44.1 M - 39.9 M 43.3 M 40.5 M - 39 M 37.9 M 40.5 M 82.2 M 38.4 M 33.5 M 49.5 M 83 M 7.61 M 28.3 M 2.37 M 3.94 M 6.85 M - 4.26 M 3.69 M 2.7 M - 2.31 M 1.35 M 1.4 M - 2.92 M 2.43 M - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Tilray (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Drug manufacturers industry

Issuer Price % 24h Market Cap Country
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 1.68 -3.44 % $ 181 M canadaCanada
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
Assertio Holdings Assertio Holdings
ASRT
$ 0.74 -3.53 % $ 52.6 M usaUSA
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
Cronos Group Cronos Group
CRON
$ 3.05 -6.88 % $ 1.61 B canadaCanada
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Aurora Cannabis Aurora Cannabis
ACB
$ 5.1 -5.59 % $ 86.3 M canadaCanada
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 4.76 -1.14 % $ 627 M usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
Pacira BioSciences Pacira BioSciences
PCRX
$ 26.64 1.33 % $ 1.23 B usaUSA
Emergent BioSolutions Emergent BioSolutions
EBS
$ 12.27 7.44 % $ 628 M usaUSA
Evoke Pharma Evoke Pharma
EVOK
$ 10.97 0.14 % $ 36.7 M usaUSA
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
Rockwell Medical Rockwell Medical
RMTI
$ 0.88 -5.2 % $ 20.5 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
$ 21.43 0.3 % $ 2.04 B franceFrance
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 3.52 -2.07 % $ 4.37 M usaUSA
Evolus Evolus
EOLS
$ 7.14 1.42 % $ 443 M usaUSA
Harrow Health Harrow Health
HROW
$ 46.39 -1.43 % $ 1.51 B usaUSA
China Pharma Holdings China Pharma Holdings
CPHI
$ 1.53 -1.92 % $ 26.7 M chinaChina
Bausch Health Companies Bausch Health Companies
BHC
$ 6.87 -0.79 % $ 2.51 B canadaCanada
Veru Veru
VERU
$ 2.39 -1.24 % $ 322 M usaUSA
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
OrganiGram Holdings OrganiGram Holdings
OGI
$ 1.81 -5.99 % $ 402 M canadaCanada
cbdMD cbdMD
YCBD
$ 1.18 -3.28 % $ 5.09 M usaUSA
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 3.04 20.16 % $ 42.7 M usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
Solid Biosciences Solid Biosciences
SLDB
$ 5.77 -1.79 % $ 236 M usaUSA
PetIQ PetIQ
PETQ
- 1.64 % $ 400 M usaUSA
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 4.34 6.9 % $ 131 M usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Perrigo Company plc Perrigo Company plc
PRGO
$ 12.77 -2.85 % $ 1.75 B usaUSA
ProPhase Labs ProPhase Labs
PRPH
$ 0.12 0.87 % $ 1.9 M usaUSA
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
Sundial Growers Sundial Growers
SNDL
$ 1.96 -11.31 % $ 3.37 M canadaCanada
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
SCYNEXIS SCYNEXIS
SCYX
$ 0.64 -0.91 % $ 30.6 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
TherapeuticsMD TherapeuticsMD
TXMD
$ 1.7 -2.86 % $ 17.7 M usaUSA
Zomedica Corp. Zomedica Corp.
ZOM
- -0.21 % $ 98 M usaUSA
Viatris Viatris
VTRS
$ 11.65 - $ 14.1 B usaUSA